Leading CROs increase adoption of WCG’s suite of solutions enabling connectivity to key clinical trial sites via unparalleled technology and staffing solutions
Global program drives collaboration to increase efficiency and reduce burden on investigational sites, accelerating clinical trials sponsored by pharmaceutical, biotechnology and medical device companies
PRINCETON, N.J., April 5, 2022 /PRNewswire/ — In response to growing demand from large, multinational and smaller clinical research organizations (CROs), WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical trials, has launched a program to augment the existing capabilities of CROs and further support the critical work they do to drive innovation in clinical trials. By providing CROs with access to its cutting-edge clinical trial operations data, facilitating working relationships with investigative sites, and streamlining workflows through purpose-built technology, the program WCG CRO’s strategic alliance enables CROs to better serve patients and research sponsors, and to accelerate the rate at which new therapies are brought to market.
Nick SlackMBE, Chairman of WCG, said: “The clinical trials industry is going through an unprecedented period of ups and downs. at the same time, capacity at investigative sites is at an all-time low, adding complexity and delays to the trials needed to bring lifesaving therapies to market in the safest and most effective way possible . the science industry in a difficult situation. There is a very serious need for smart alliances between leading service organizations to address challenges head-on, which is why we are expanding our work with our long-standing CRO partners.
“We are always looking for ways to provide the highest quality services to protect patients and efficiently conduct clinical trials for our sponsors, and our partnership with WCG helps us achieve these goals,” said Peter Benton, President and Co-CEO, Global Clinical Trials. “It provides the level of expertise to ensure scientific rigor, scalability to support our customers’ global footprints, and flexibility to better meet needs and reduce the load on research sites participating in clinical trials.
Engaged by 10 of the top 10 global CROs and 25 of the top 25 specialty CROs, WCG is a sought-after partner for CROs conducting clinical trials for pharmaceutical, biotechnology and medical device companies of all sizes worldwide. The WCG CRO Strategic Alliance Program enables CROs to leverage WCG’s connected position in the clinical trial ecosystem to reduce study complexity and ease the burden on research teams at investigational sites, streamlining multi-vendor relationships into a harmonized and efficient engagement with a single partner.
“To ensure that life-saving new therapies continuously progress through the clinical trial process, CROs are mission critical, so it is imperative that they are able to navigate a highly research site environment. fractured,” Slack added. “We’re here to help our long-serving CROs do just that. With our deep domain expertise and 50 years of leadership in supporting test sites, WCG has a proven track record in solving the constraints of resources and innovation for the future. Providing such strengthening capabilities to partners, who share our commitment to accelerating the development of new therapies and life-saving treatments for patients, is part of our ongoing efforts to meet the needs of research clinic with passion and determination.”
An agile, multi-solution service provider that reaches 97% of clinical trials conducted globally, WCG enables CROs to realize significant efficiencies by helping them improve study enrollment predictability, protect endpoints assessment, align with industry benchmarks and leading practices, and guard against unforeseen and costly changes. Today, WCG serves more than 140 CROs in therapeutic and specialty areas such as oncology, CNS, immunology, and rare diseases, among others. The company’s IRB division alone has helped CROs conduct more than 36,000 clinical trials at more than 183,000 sites, underscoring WCG’s commitment to supporting the research stakeholder ecosystem.
From IRB ethics review to patient recruitment; increased site to electronic clinical outcome assessment (eCOA); endpoint protection to imaging, security and training technology platforms; to patient advisory boards and data monitoring committees, WCG ensures that CROs have the optimal resources to best serve their clinical trial sponsor clients.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two segments, Ethical Review and Clinical Trial Solutions (CTS), WCG enables biopharmaceutical companies, CROs and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of data protection. human participants. For more information, please visit www.wcgirb.com, www.wcgclinical.com or follow us on Twitter @WCGClinical Where LinkedIn.